MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-06-2025
Pacira BioSciences Operating Expenses 2011-2026 | PCRX
Annual Operating Expenses Pacira BioSciences
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | 279 M | 233 M | 219 M | 198 M | 168 M | 125 M | 84.1 M | 56.2 M | 35 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 279 M | 35 M | 155 M |
Quarterly Operating Expenses Pacira BioSciences
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 121 M | 102 M | 97.3 M | 90.2 M | 82.9 M | 79.4 M | 77.6 M | 81.5 M | 70.6 M | 70.9 M | 86.7 M | 83.3 M | 75.4 M | 89.2 M | 76.1 M | 67.7 M | 70.1 M | 57.1 M | 57.3 M | 55 M | 203 M | 53 M | 50 M | 45.9 M | 43.4 M | 36.1 M | 29.2 M | 30.2 M | 26.3 M | 24.2 M | 19 M | 18.9 M | - | 12.7 M | 12.2 M | 11 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 203 M | 11 M | 63 M |
Operating Expenses of other stocks in the Drug manufacturers industry
| Issuer | Operating Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Adamis Pharmaceuticals Corporation
ADMP
|
38.9 M | - | 0.86 % | $ 117 M |  USA |
 |
AcelRx Pharmaceuticals
ACRX
|
40.3 M | - | 7.5 % | $ 6.35 M | USA |
 |
Agile Therapeutics
AGRX
|
30.5 M | - | 10.11 % | $ 58.2 M | USA |
 |
Assertio Holdings
ASRT
|
133 M | $ 18.02 | -2.12 % | $ 115 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
213 M | - | - | $ 754 M | USA |
 |
Catalent
CTLT
|
512 M | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
44.6 M | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
113 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
763 M | - | - | $ 28.9 M |  Irlanda |
 |
Alimera Sciences
ALIM
|
71.8 M | - | - | $ 142 M | USA |
 |
Athenex
ATNX
|
96.7 M | - | -23.39 % | $ 1.76 M | USA |
 |
Evoke Pharma
EVOK
|
12.6 M | - | - | $ 36.6 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
196 M | - | - | $ 2.06 B |  France |
 |
Cumberland Pharmaceuticals
CPIX
|
35.2 M | $ 3.11 | -0.96 % | $ 43.7 M | USA |
 |
Cronos Group
CRON
|
154 M | $ 2.55 | 0.79 % | $ 1.33 B |  Canada |
 |
Calliditas Therapeutics AB (publ)
CALT
|
213 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
106 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Bausch Health Companies
BHC
|
4.96 B | $ 5.39 | 0.75 % | $ 1.97 B | Canada |
 |
Harrow Health
HROW
|
174 M | $ 37.29 | 1.52 % | $ 1.37 B | USA |
 |
Aurora Cannabis
ACB
|
183 M | $ 3.48 | 1.46 % | $ 86.3 M | Canada |
 |
Canopy Growth Corporation
CGC
|
197 M | $ 1.09 | 4.81 % | $ 117 M | Canada |
 |
Jupiter Wellness
JUPW
|
12.5 M | - | - | $ 33.6 M | USA |
 |
Lannett Company
LCI
|
209 M | - | 1.15 % | $ 7.11 M | USA |
 |
Evolus
EOLS
|
107 M | $ 4.24 | 3.67 % | $ 273 M | USA |
 |
Emergent BioSolutions
EBS
|
558 M | $ 8.45 | 0.72 % | $ 433 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
103 M | - | - | $ 193 M | Canada |
 |
OrganiGram Holdings
OGI
|
41.4 M | $ 1.44 | 3.6 % | $ 402 M | Canada |
 |
Organogenesis Holdings
ORGO
|
368 M | $ 2.29 | -4.18 % | $ 302 M | USA |
 |
PetIQ
PETQ
|
138 M | - | 1.64 % | $ 400 M | USA |
 |
Sundial Growers
SNDL
|
102 K | $ 1.38 | 1.47 % | $ 3.37 M | Canada |
 |
ProPhase Labs
PRPH
|
47.1 M | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
304 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
22.5 M | - | -4.76 % | $ 65.3 M | USA |
 |
Relmada Therapeutics
RLMD
|
59.1 M | $ 7.61 | 8.56 % | $ 300 M | USA |
 |
SCYNEXIS
SCYX
|
36.7 M | $ 0.99 | -0.4 % | $ 49.4 M | USA |
 |
OptiNose
OPTN
|
129 M | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
44.2 M | - | -27.8 % | $ 2.56 M | USA |
 |
Solid Biosciences
SLDB
|
179 M | $ 8.1 | 1.0 % | $ 709 M | USA |
 |
Tilray
TLRY
|
1.52 B | $ 6.72 | -0.44 % | $ 4.15 B | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
9.18 M | $ 2.41 | 5.24 % | $ 2.99 M | USA |
 |
Veru
VERU
|
44 M | $ 2.43 | -4.71 % | $ 328 M | USA |
 |
Viatris
VTRS
|
5.67 B | $ 13.61 | 0.29 % | $ 16.3 B | USA |
 |
cbdMD
YCBD
|
28.9 M | $ 0.65 | -6.59 % | $ 2.8 M | USA |
 |
Zomedica Corp.
ZOM
|
14.1 M | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
35.3 M | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
31.1 M | $ 0.93 | -0.98 % | $ 33.5 M | USA |
 |
Tricida
TCDA
|
153 M | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
3.11 M | $ 0.66 | 5.66 % | $ 2.83 M |  China |
 |
TherapeuticsMD
TXMD
|
7.41 M | $ 2.05 | - | $ 23.7 M | USA |